Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the last decade, the inhibition of protein-protein interactions (PPIs) has emerged from both academic and private research as a new way to modulate the activity of proteins. Inhibitors of these original interactions are certainly the next generation of highly innovative drugs that will reach the market in the next decade. However, in silico design of such compounds still remains challenging. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe this particular PPI chemical space through the presentation of 2P2I(DB), a hand-curated database dedicated to the structure of PPIs with known inhibitors. We have analyzed protein/protein and protein/inhibitor interfaces in terms of geometrical parameters, atom and residue properties, buried accessible surface area and other biophysical parameters. The interfaces found in 2P2I(DB) were then compared to those of representative datasets of heterodimeric complexes. We propose a new classification of PPIs with known inhibitors into two classes depending on the number of segments present at the interface and corresponding to either a single secondary structure element or to a more globular interacting domain. 2P2I(DB) complexes share global shape properties with standard transient heterodimer complexes, but their accessible surface areas are significantly smaller. No major conformational changes are seen between the different states of the proteins. The interfaces are more hydrophobic than general PPI's interfaces, with less charged residues and more non-polar atoms. Finally, fifty percent of the complexes in the 2P2I(DB) dataset possess more hydrogen bonds than typical protein-protein complexes. Potential areas of study for the future are proposed, which include a new classification system consisting of specific families and the identification of PPI targets with high druggability potential based on key descriptors of the interaction. CONCLUSIONS: 2P2I database stores structural information about PPIs with known inhibitors and provides a useful tool for biologists to assess the potential druggability of their interfaces. The database can be accessed at http://2p2idb.cnrs-mrs.fr.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Flow chart indicating how the 2P2IDB dataset was build from data mining. Two separate approaches were used to retrieve protein/protein complexes with known inhibitors for which structural information was available. The protein databank was search through the Dockground server [23] which led to 202 complexes that were filtered using an advanced query and manual inspection of the interface to give 9 protein/protein complexes and 25 protein/inhibitor complexes. Exhaustive search of the literature led to the discovery of 8 protein complexes corresponding to 31 protein/ligand complexes.](https://figures.cochat.ai/paper-figures/c7f8527f33f940a6a4ee7d73e37cfa85/atomic-analysis-of-protein-protein-interfaces-with-known-inhibitors-the-2p2i-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, many PPI modulators have been developed and some of these have even successfully entered the clinic [30–33].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“To date, numerous modulators have been developed to target PPIs, and many of them have successfully entered the clinic.312–316”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [312]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,893
Algorithm AS 136: A K-Means Clustering Algorithm
Hartigan, J. A., & Wong, M. A. (1979) · Applied Statistics · doi:10.2307/2346830 · Cited by 14,523 · cited 1×
“Clustering of the PPIs into three groups was performed using the K-mean method”
MethodHow many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505 · cited 1×
“The number of currently available drug targets is very limited [18].”
BackgroundPrinciples of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 1×
“I 2 MDM2/p53 1ycr 1ycq 3 PubMed 600 [28]”
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960 · cited 2×
“preclinical stage of investigation [8,17].”
BackgroundADE-4: a multivariate analysis and graphical display software
Thioulouse, J., Chessel, D., Dole´dec, S., & Olivier, J.-M. (1997) · Statistics and Computing · doi:10.1023/a:1018513530268 · Cited by 1,620 · cited 1×
“org) and the ade4 package [25].”
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467
Journal of the Royal Statistical Society: Series C (Applied Statistics)
(2023) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/(issn)1467-9876 · Cited by 1,178
Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites
Laurie, A. T. R., & Jackson, R. M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti315 · Cited by 1,047 · cited 2×
“The parameters should be pre-calculated using online web servers (ProtorP [10], PDBSum [16] or Q-SiteFinder [15]) and entered on the 2P2IDB website.”
MethodStructural basis of IAP recognition by Smac/DIABLO
Wu, G., Chai, J., Suber, T. L., Wu, J.-W., Du, C., Wang, X., & Shi, Y. (2000) · Nature · doi:10.1038/35050012 · Cited by 861 · cited 2×
“I 3 XIAP BIR3/CASPASE 9 1nw9 2 PubMed 20 [29]”
Cellular and Molecular Life Sciences : CMLS
Domon, M. M., Nasir, M. N., Matar, G., Pikuła, S., Besson, F., & Bandorowicz‐Pikuła, J. (2011) · Cited by 615
Structural Characterisation and Functional Significance of Transient Protein–Protein Interactions
Nooren, I. M. A., & Thornton, J. M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01281-0 · Cited by 587 · cited 3×
“Parameters characteristic of weak and strong transient dimers as defined by Nooren and Thornton [ 11 ] were incorporated in a new PCA analysis .”
BackgroundMethodInfluentialLaskowski, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn860 · Cited by 583 · cited 2×
“The parameters should be pre-calculated using online web servers (ProtorP [10], PDBSum [16] or Q-SiteFinder [15]) and entered on the 2P2IDB website.”
MethodCrystal Structure of the Cytoplasmic Domain of the Type I TGF β Receptor in Complex with FKBP12
Huse, M., Chen, Y.-G., Massagué, J., & Kuriyan, J. (1999) · Cell · doi:10.1016/s0092-8674(00)80555-3 · Cited by 445 · cited 1×
“II 8 FKBP12/TGFR 1b6c 17 PDB na [33]”
Journal of Computer-Aided Molecular Design
(2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/10822.1573-4951 · Cited by 401
Predicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310 · cited 5×
“However, they were used in the PCA analysis because they are known to play an important role in protein-protein specific interaction [14].”
BackgroundMethodResultInfluentialBODE, W., PAPAMOKOS, E., & MUSIL, D. (1987) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1987.tb13566.x · Cited by 287
Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress
Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281 · cited 1×
“These interactions control processes involved in both normal and pathological pathways, which include signal transduction, cell adhesion, cellular proliferation, growth, differentiation, viral self-assembly, programmed cell death and cytoskeleton structure (for a review refer to [3]).”
BackgroundSYMMETRY, FORM, AND SHAPE: Guiding Principles for Robustness in Macromolecular Machines
Tama, F., & Brooks, C. L. (2006) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.35.040405.102010 · Cited by 266 · cited 1×
“) or, even more importantly, clinically, and the inhibition of the PPI should not be associated with toxicity; ii) Key residues involved in the interaction and defining hot spots should be characterized through mutagenesis analyses, alanine scanning or by server prediction; iii) Structural information on the PPI compl…”
BackgroundAnnual review of biophysics and biomolecular structure
Engelman, D. M., Cantor, C. R., Pollard, T. D., Stroud, R. M., & Rees, D. C. (1992) · Cited by 227
The Structure of Interleukin-2 Complexed with Its Alpha Receptor
Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N., & Garcia, K. C. (2005) · Science · doi:10.1126/science.1109745 · Cited by 212 · cited 1×
“II 9 IL-2/IL-2R 1z92 8 PubMed 10 [34]”
Protein–protein interactions as targets for small molecule drug discovery
Fry, D. C. (2006) · Peptide Science · doi:10.1002/bip.20608 · Cited by 206
ProtorP: a protein–protein interaction analysis server
Reynolds, C., Damerell, D., & Jones, S. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btn584 · Cited by 185 · cited 4×
“The parameters should be pre-calculated using online web servers (ProtorP [10], PDBSum [16] or Q-SiteFinder [15]) and entered on the 2P2IDB website.”
BackgroundMethodResultInfluentialComplementarity of Structure Ensembles in Protein-Protein Binding
Grünberg, R., Leckner, J., & Nilges, M. (2004) · Structure · doi:10.1016/j.str.2004.09.014 · Cited by 181 · cited 1×
“The formation of heterodimeric complexes can lead to large rearrangements of the two protein partners [12].”
BackgroundEmerging classes of protein–protein interaction inhibitors and new tools for their development
Pagliaro, L., Felding, J., Audouze, K., Nielsen, S. J., Terry, R. B., Krog-Jensen, C., & Butcher, S. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.006 · Cited by 168 · cited 1×
“Several other studies have also focused on subsets of small molecules that disrupt PPIs [5,6,7,8].”
BackgroundThe X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2
Abbate, E. A., Berger, J. M., & Botchan, M. R. (2004) · Genes & Development · doi:10.1101/gad.1220104 · Cited by 160 · cited 1×
“II 7 E2/E1 1tue 1 PubMed na [32]”
Higueruelo, A. P., Schreyer, A., Bickerton, G. R. J., Pitt, W. R., Groom, C. R., & Blundell, T. L. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00889.x · Cited by 157 · cited 4×
“This result indicates that PPIs with known inhibitors are more hydrophobic than typical heterodimers, which can be correlated to the observation that small molecule PPI modulators are hydrophobic [4].”
BackgroundResultInfluentialThe interface of protein-protein complexes: Analysis of contacts and prediction of interactions
Bahadur, R. P., & Zacharias, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7451-x · Cited by 150 · cited 6×
“The interfaces found in 2P2I DB were then compared to those of representative datasets of heterodimeric complexes from Bahadur and Zacharias [9] or from the ProtorP parameters (http://www.bioinformatics.sussex.ac.uk/ protorp/ and [10].”
BackgroundResultInfluentialTrapping Moving Targets with Small Molecules
Lee, G. M., & Craik, C. S. (2009) · Science · doi:10.1126/science.1169378 · Cited by 145 · cited 3×
“) or, even more importantly, clinically, and the inhibition of the PPI should not be associated with toxicity; ii) Key residues involved in the interaction and defining hot spots should be characterized through mutagenesis analyses, alanine scanning or by server prediction; iii) Structural information on the PPI compl…”
BackgroundSmall Molecule Inhibitors of Protein–Protein Interactions
Berg, T. (2012) · Springer eBooks · doi:10.1007/978-3-642-16712-6_100964 · Cited by 119
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 99 · cited 1×
“Based on this new focus, it is now more and more commonly accepted that protein-protein complexes are an important class of therapeutic targets [2].”
BackgroundD ockground resource for studying protein–protein interfaces
Douguet, D., Chen, H.-C., Tovchigrechko, A., & Vakser, I. A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl447 · Cited by 84 · cited 2×
“The protein databank was search through the Dockground server [23] which led to 202 complexes that were filtered using an advanced query and manual inspection of the interface to give 9 protein/protein complexes and 25 protein/inhibitor complexes.”
MethodFry, D. (2008) · Current Protein & Peptide Science · doi:10.2174/138920308784533989 · Cited by 77 · cited 1×
“Several other studies have also focused on subsets of small molecules that disrupt PPIs [5,6,7,8].”
BackgroundWhat induces pocket openings on protein surface patches involved in protein–protein interactions?
Eyrisch, S., & Helms, V. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9239-y · Cited by 74 · cited 1×
“) or, even more importantly, clinically, and the inhibition of the PPI should not be associated with toxicity; ii) Key residues involved in the interaction and defining hot spots should be characterized through mutagenesis analyses, alanine scanning or by server prediction; iii) Structural information on the PPI compl…”
BackgroundIyer, S., Wei, S., Brew, K., & Acharya, K. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607625200 · Cited by 72 · cited 1×
“40 [35]”
Li, W., Adams, T. E., Nangalia, J., Esmon, C. T., & Huntington, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711055105 · Cited by 61 · cited 1×
“II 13 Thrombin/Protein C inhibitor 3b9f 1 PDB na [40]”
BackgroundA Tick Protein with a Modified Kunitz Fold Inhibits Human Tryptase
Paesen, G. C., Siebold, C., Harlos, K., Peacey, M., Nuttall, P. A., & Stuart, D. I. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.03.011 · Cited by 59 · cited 1×
“02 [41]”
Solution Structure of ZipA, a Crucial Component ofEscherichia coliCell Division
Moy, F. J., Glasfeld, E., Mosyak, L., & Powers, R. (2000) · Biochemistry · doi:10.1021/bi0009690 · Cited by 56 · cited 1×
“I 5 ZipA/FtsZ 1f47 4 PubMed 20,000 [30]”
Horn, J. R., Ramaswamy, S., & Murphy, K. P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00783-6 · Cited by 48
Radisky, E. S., Kwan, G. F., Lu, C.-J. K., & Koshland, D. E. (2004) · Biochemistry · doi:10.1021/bi048797k · Cited by 48 · cited 1×
“029 [37–39]”
Peptide segments in protein-protein interfaces
Pal, A., Chakrabarti, P., Bahadur, R. P., Rodier, F., & Janin, J. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0010-7 · Cited by 44 · cited 1×
“While considering the length of the segment, only interface residues are counted [13,24].”
BackgroundRedzynia, I., Ljunggren, A., Bujacz, A., Abrahamson, M., Jaskólski, M., & Bujacz, G. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06824.x · Cited by 40 · cited 1×
“036 [31]”
Small-Molecule Inhibitors of Protein–Protein Interactions
Berg, T. (2010) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781848163409_0012 · Cited by 38 · cited 1×
“preclinical stage of investigation [8,17].”
Global Orientation of Bound MMP-3 and N-TIMP-1 in Solution via Residual Dipolar Couplings,
Arumugam, S., & Doren, S. R. V. (2003) · Biochemistry · doi:10.1021/bi034545s · Cited by 20
Novak, W., Wang, H., & Krilov, G. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9237-0 · Cited by 15
Roche, P., & Morelli, X. (2011) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805142711101010118 · Cited by 5 · cited 2×
“In the last decade, the inhibition of protein-protein interactions (PPIs) has emerged from both academic and private research as a new way to modulate the activity of proteins (for an in depth review see Roche and Morelli [1]).”
BackgroundSelf-citation
Cited by
On the binding affinity of macromolecular interactions: daring to ask why proteins interact
Kastritis, P. L., & Bonvin, A. M. J. J. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0835 · Cited by 520
“Since protein–protein interfaces are larger than classical enzymatic binding sites, inhibitors or modulators that have been designed for these are also larger in size [317].”
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Smith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Druggable protein–protein interactions – from hot spots to hot segments
London, N., Raveh, B., & Schueler-Furman, O. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.011 · Cited by 223
Metadata
- Authors
- Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Morelli, Xavier
- Roche, Philippe
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-03-09
- Volume
- 5
- Issue
- 3
- Pages
- e9598
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2834754
- OpenAlex
- W2102791444
- Cited by
- 126
- References
- 48
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 15 · 2014: 11 · 2013: 22 · 2012: 20
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- protein-protein interaction, PPI inhibitors, protein-protein interfaces, hydrogen bonding, druggability assessment, structure-based drug design
- MeSH terms
- Biophysics, Humans, Hydrogen Bonding, Protein Conformation, Salts, Models, Statistical, Protein Structure, Secondary, Dimerization, Computational Biology, Internet, Principal Component Analysis, Protein Interaction Mapping, Databases, Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.